Efficacy and safety of immune checkpoint inhibitors combined with TKIs for recurrent or metastatic cervical cancer with PIK3CA mutation

Lele Chang, Yaxin Kang, Mingxuan Zhu, Jing Liu, Chunyan Lan, Qin Xu · 2026

Read Efficacy and safety of immune checkpoint inhibitors combined with TKIs for recurrent or metastatic cervical cancer with PIK3CA mutation by Lele Chang, Yaxin Kang, Mingxuan Zhu, Jing Liu, Chunyan Lan, Qin Xu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0350571.txt.

Description

Chang and five co-authors published a 2026 PLOS ONE study on hard-to-treat cervical cancer. The cancer had come back or spread to other parts of the body. The team tested the safety and effect of pairing immune checkpoint inhibitors with a class of drugs called TKIs. All patients carried a gene change named PIK3CA. Pairing drug types is a common hope when single drugs stop working.

Catalog record

CREATORLele Chang, Yaxin Kang, Mingxuan Zhu, Jing Liu, Chunyan Lan, Qin Xu
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE35122
LICENSECC_BY
RIGHTSCC BY
SOURCEPLOS

Source: https://doi.org/10.1371/journal.pone.0350571

Browse the full library · About the Tower of Babel